Why Vaxart Stock Is Retreating Today

What happened

Shares of the clinical-stage biotech Vaxart (NASDAQ: VXRT) slid by as much as 11.3% in early-morning action Wednesday. The developmental vaccine company's shares appear to be reacting negatively to the news that Johnson & Johnson (NYSE: JNJ) has advanced its single-shot COVID-19 vaccine candidate, known as Ad26.COV2.S (JNJ-78436735), into a pivotal-stage trial.

Although the study's full results won't be ready until March 2023, J&J's chief scientific officer, Paul Stoffels, said in a press conference that the vaccine's safety and efficacy profile could become known quantities by year's end. That's potentially bad news for other COVID-19 vaccine developers like Vaxart who are only now entering early-stage trials.  

A gloved hand holds a vial of blood labeled Coronavirus

Image Source: Getty Images.

Vaxart's shares have bounced back to a degree since hitting their intraday low, but they are still down by 8.23% as of 10:23 a.m. EDT Wednesday.

So what

Vaxart is reportedly gearing up to begin patient enrollment for a phase 1 trial of its oral COVID-19 vaccine this month. While the start of human trials is an important milestone, the fact is that Vaxart appears to be at least a year behind the leaders in the space, such as J&J.

On a positive note, Vaxart's oral vaccine could sport several key advantages over the injected products, which may help it carve out a profitable niche. That said, the first wave of COVID-19 vaccines are surely going to gobble up the lion's share of the market. 

Now what

Is this dip a buying opportunity? Vaxart's shares should rebound nicely if the company reports positive phase 1 results for its COVID-19 vaccine candidate later this year. That said, this is a risky developmental-stage biotech stock that is arguably suited only for aggressive investors. 

10 stocks we like better than Vaxart, Inc
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Vaxart, Inc wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of August 1, 2020


George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.